BioCardia, Inc. Increase Decrease In Operating Lease Liability
BioCardia, Inc. (BCDA) reported Increase Decrease In Operating Lease Liability of -$256.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-12
- BioCardia, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$128.00K.
- BioCardia, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$128.00K.
- BioCardia, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$187.00K.
- BioCardia, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$64.00K.
- BioCardia, Inc. increase decrease in operating lease liability for fiscal 2025 was -$500.00K.
- BioCardia, Inc. increase decrease in operating lease liability for fiscal 2024 was -$483.00K.
- BioCardia, Inc. increase decrease in operating lease liability for fiscal 2023 was -$316.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 3 month as first filed | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 6 month as first filed | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month | Increase Decrease In Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$128.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$256.00K 10-Q · filed 2026-08-12 | -$443.00K derived: sum of 3 quarters · filed 2026-08-12 | -$507.00K derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2026-03-31 | -$128.00K 10-Q · filed 2026-05-15 | -$315.00K derived: sum of 2 quarters · filed 2026-05-15 | -$379.00K derived: sum of 3 quarters · filed 2026-05-15 | -$503.00K derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-12-31 | -$187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$251.00K derived: sum of 2 quarters · filed 2026-03-24 | -$375.00K derived: sum of 3 quarters · filed 2026-08-12 | -$500.00K 10-K · filed 2026-03-24 | |||
| 2025-09-30 | -$64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$188.00K derived: sum of 2 quarters · filed 2026-08-12 | -$313.00K 10-Q · filed 2025-11-12 | -$526.00K derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-06-30 | -$124.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$249.00K 10-Q · filed 2026-08-12 | -$206.00K 10-Q · filed 2025-08-11 | -$462.00K derived: sum of 3 quarters · filed 2026-08-12 | -$555.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$125.00K 10-Q · filed 2026-05-15 | -$101.00K 10-Q · filed 2025-05-14 | -$338.00K derived: sum of 2 quarters · filed 2026-05-15 | -$431.00K derived: sum of 3 quarters · filed 2026-05-15 | -$521.00K derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | -$213.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$306.00K derived: sum of 2 quarters · filed 2026-03-24 | -$396.00K derived: sum of 3 quarters · filed 2026-03-24 | -$483.00K 10-K · filed 2026-03-24 | -$364.00K 10-K · filed 2025-03-26 | ||
| 2024-09-30 | -$93.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-11-12 | -$183.00K derived: sum of 2 quarters · filed 2025-11-12 | -$270.00K 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | -$90.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2025-10-29 | -$177.00K 10-Q/A · filed 2025-10-29 | |||||
| 2024-03-31 | -$87.00K 10-Q · filed 2025-05-14 | ||||||
| 2023-12-31 | -$316.00K 10-K · filed 2025-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |